AN2 Therapeutics, Inc.: Commodore Capital LP amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Commodore Capital LP amended its Schedule 13G filing on AN2 Therapeutics, Inc., disclosing a change in its passive stake in the clinical-stage biopharmaceutical company. The amendment was filed with the SEC under accession number 0001831942-26-000048. The filing signals a shift in the institutional investor's position, though the exact size and direction of the change were not specified in the headline. Investors will watch for further 13G amendments or 13D filings to gauge whether Commodore's stance remains passive or turns activist.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
AN2 Therapeutics, Inc., Commodore Capital LP